Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
Shingo Matsumoto,Alasdair D Henderson,Li Shen,Toru Kondo,Mingming Yang,Ross T Campbell,Inder S Anand,Rudolf A de Boer,Akshay S Desai,Carolyn S P Lam,Aldo P Maggioni,Felipe A Martinez,Milton Packer,Margaret M Redfield,Jean L Rouleau,Dirk J Van Veldhuisen,Muthiah Vaduganathan,Faiez Zannad,Michael R Zile,Pardeep S Jhund,Scott D Solomon,John J V McMurray
DOI: https://doi.org/10.1002/ejhf.3383
2024-08-31
Abstract:Aims: In the absence of randomized trial evidence, we performed a large observational analysis of the association between beta-blocker (BB) use and clinical outcomes in patients with heart failure (HF) and mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). Methods and results: We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER). The primary outcome was the composite of cardiovascular death or HF hospitalization. Among the 16 951 patients included, the mean left ventricular ejection fraction (LVEF) was 56.8%, and 13 400 (79.1%) had HFpEF (LVEF ≥50%). Overall, 12 812 patients (75.6%) received a BB. The median bisoprolol-equivalent dose of BB was 5.0 (Q1-Q3: 2.5-5.0) mg with BB continuation rates of 93.1% at 2 years (in survivors). The unadjusted hazard ratio (HR) for the primary outcome did not differ between BB users and non-users (HR 0.98, 95% confidence interval [CI] 0.91-1.05), but the adjusted HR was lower in BB users than non-users (0.81, 95% CI 0.74-0.88), and this association was maintained across LVEF (pinteraction = 0.88). In subgroup analyses, the adjusted risk of the primary outcome was similar in BB users and non-users with or without a history of myocardial infarction, hypertension, or a baseline heart rate <70 bpm. By contrast, a better outcome with BB use was seen in patients with atrial fibrillation compared to those without atrial fibrillation (pintreraction = 0.02). Conclusions: In this observational analysis of non-randomized BB treatment, there was no suggestion that BB use was associated with worse HF outcomes in HFmrEF/HFpEF, even after extensive adjustment for other prognostic variables.